Know Cancer

forgot password

A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Phase 1
18 Years
90 Years
Open (Enrolling)
Relapsed or Refractory Lymphoid Malignancies

Thank you

Trial Information

A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Inclusion Criteria:

1. Lymphoid malignancy that has relapsed or is refractory after two or more treatments
that are FDA approved or are commonly used clinically.

2. Subjects must have progressive disease requiring therapy. Subjects who are
candidates for observation only are not eligible.

3. Subjects are either not currently considered to be candidates or refuse potentially
curative therapies including peripheral stem cell or bone marrow transplant

4. Subjects must have measurable disease as per disease specific criteria

5. Must have received their last chemotherapy, biologic, radiotherapy, or
investigational therapy at least 4 weeks prior to enrollment; 12 weeks from their
last radioimmunotherapy; 3 months if the last therapy was bone marrow/ peripheral
stem cell transplant.

6. Age >18 years

7. ECOG performance status <2

8. Normal Ejection Fraction on ECHO scan

9. Subjects must have normal organ and marrow function as defined below:

Absolute neutrophil count >1000/mL Platelets >75,000/mL For subjects with known
marrow infiltration, ANC ≥500 and platelets ≥30,000 Total bilirubin <1.5 X
institutional upper limit of normal (ULN) (<2X ULN for subjects with Gilbert's
syndrome) AST (SGOT) and ALT (SGPT) <3 X institutional ULN (for subjects with hepatic
involvement <5 X institutional ULN) PT/INR and aPTT within 1.5 X institutional ULN
Creatinine <1.5 X institutional ULN OR Creatinine clearance >60 mL/min/1.73 m2 for
subjects with creatinine levels above institutional normal

10. Women of childbearing potential must have had a prior hysterectomy or have a negative
serum pregnancy test and be using adequate contraception prior to study entry and
must agree to use adequate contraception from study entry through at least 6 months
after discontinuation of study drug. Men must also agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to
study entry and from study entry through at least 6 months after discontinuation of
study drug. Should a woman enrolled in the study or a female partner of a man
enrolled in the study become pregnant or suspect she is pregnant while participating
in this study or within 6 months after discontinuation of study, she should inform
the Investigator immediately.

11. Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Subjects who meet any of the following criteria will not be eligible for participation in
the study:

1. Currently receiving any therapeutic treatment for lymphoid malignancies including
other investigational agents

2. Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors

3. Active CNS involvement, uncontrolled seizure disorder, or active neurologic disease

4. History of a Grade 4 allergic reaction attributed to humanized or human monoclonal
antibody therapy

5. Significant intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

6. Pregnant women or nursing women

7. Ongoing malignancies or malignancies in remission <3 years other than the lymphoid
malignancies included in this trial. Patients with history of known skin cancers
including non-melanotic skin cancers within the past 3 years will not be included in
this trial. The following prior malignancies are allowable irrespective of when they
occurred: in situ carcinoma of the cervix, in situ ductal breast cancer, and
low-grade local bladder cancer.

8. Subjects with known HIV infection

9. Known bleeding disorder or coagulopathy

10. Subjects receiving heparin, warfarin, or other similar anticoagulants, except for
subjects on low molecular weight heparin for DVT/PE prophylaxis. Note: Subjects may
be receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents.

11. New York Heart Association Classification II, III, or IV

12. Subjects with a blood pressure of >140/90 mmHg that is not responsive to medical
therapy. Subjects taking antihypertensive medications must be taking ≤2 medications
to obtain this level of blood pressure control.

13. Subjects with EKG evidence of ischemia or ≥Grade 2 ventricular arrhythmia, subjects
who have a history of acute myocardial infarction within 6 months, or subjects with
unstable angina.

14. Subjects with known clinically significant gastrointestinal disease including, but
not limited to, inflammatory bowel disease

15. Subjects with diarrhea at time of enrollment or have an ongoing requirement for anti
diarrheal therapy

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety profile of OMP-52M51 in subjects with relapsed or refractory lymphoid malignancies

Outcome Time Frame:

Subjects will be assessed for DLTs from Days 0-29. Adverse events will be reported through 30 days after the last dose

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

October 2012

Completion Date:

June 2015

Related Keywords:

  • Relapsed or Refractory Lymphoid Malignancies
  • Phase 1
  • Dose escalation
  • relapsed or refractory
  • lymphoid malignancies
  • Neoplasms



University of Rochester Medical Center Rochester, New York  14642
University of Nebraska Medical Center Omaha, Nebraska  68198-3330
Ohio State University Comprehensive Cancer Center Columbus, Ohio  
Sara Cannon Research Institute Nashville, Tennessee  37203
Cornell University Division of Hematology and Medical Oncology New York, New York  10065